Close Menu

NEW YORK – Gene editing company Inscripta announced on Tuesday that it has raised $125 million in a Series D financing round.

Paladin Capital Group led the round, with support from existing investors and new investors JS Capital Management and Oak HC/FT. The company said it has now raised $259.5 million — its Series C round raised a total of $105.5 million after two expansions.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.